AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

2019 Pipeline Insight Urinary Incontinence - ResearchAndMarkets.com

February 28, 2019

DUBLIN--(BUSINESS WIRE)--Feb 28, 2019--The “Urinary Incontinence - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Urinary Incontinence development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Scope of the Report

  • The report provides a snapshot of the pipeline development for Urinary Incontinence
  • The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for Urinary Incontinence
  • The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Urinary Incontinence
  • The report also covers the dormant and discontinued pipeline projects related to Urinary Incontinence

Reasons to Buy

  • Establish comprehensive understanding of the pipeline activity across this Urinary Incontinence to formulate effective R&D strategies
  • Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
  • Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Urinary Incontinence therapeutics
  • Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

Companies Mentioned

  • Astellas Pharma Inc.
  • Celogos
  • Cook MyoSite Incorporated
  • FemmePharma Global Healthcare Inc.
  • GTx Inc.
  • Innovacell Biotechnologie AG
  • Ipsen S.A.
  • Outpost Medicine Limited
  • Taiho Pharmaceutical Co. Ltd.
  • Takeda Pharmaceutical Company Limited
  • TheraVida Inc.

Topics Covered

1. Report Introduction

2. Urinary Incontinence Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for Urinary Incontinence

4. Comparative Analysis

5. Products in Clinical Stage

  • Product Description
  • Research and Development
  • Product Development Activities

6. Products in Pre-Clinical and Discovery Stage

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment

  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

8. Inactive Products

  • Product Description
  • Research and Development
  • Product Development Activities

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/zg6t7v/2019_pipeline?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190228005678/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Urological Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 02/28/2019 11:08 AM/DISC: 02/28/2019 11:08 AM

http://www.businesswire.com/news/home/20190228005678/en